Entera Bio Ltd. announced that its pre-clinical manuscript entitled "Oral Delivery Technology Enabling Gastro-Mucosal Absorption of Glucagon-Like-Peptide-2alog (GLP-2), Teduglutide - A Novel Approach for Injection-Free Treatment of Short Bowel Syndrome" has been accepted for publication by the International Journal of Peptide Research and Therapeutics. Short bowel syndrome (SBS) is a rare and potentially life-threatening malabsorptive condition caused by a significant loss of functional bowel mass (secondary to congenital defects or disease-associated loss of absorption) or physical bowel mass (secondary to extensive intestinal resection). SBS patients have a reduced ability to absorb nutrients and fluids and are at risk of malnutrition, unintended weight loss and additional symptoms due to the loss of essential vitamins and minerals1.

SBS is the most common cause of chronic intestinal failure, accounting for approximately 75% of cases of chronic intestinal failure in adults and 50% such events in children.2 Teduglutide, a GLP-2 analog and mainstay treatment for SBS, is known to enhance intestinal absorption. Teduglutide treatment requires daily sub-cutaneous injections. "There are several new generation GLP-2 analogs under development which may also require chronic injections.

As part of R&D initiatives, Entera is leveraging on its proprietary platform to enable a potential first-in-class oral GLP-2, daily tablet treatment for patients with short bowel syndrome (SBS) and other disorders requiring parenteral nutrition.